Targeted Oncology

Reassessing 7+3 in AML: New Trial Data Challenge Status Quo

PARADIGM data suggest azacitidine plus venetoclax improves AML event-free survival vs 7+3 with less toxicity; survival looks ...
GovInfoSecurity

Rethinking AML for Real-Time Payments

Instant payments are reshaping financial crime controls as speed and the irreversibility of transactions strain anti-money ...
Targeted Oncology

Dr Richard Stone Weighs the Future of 7+3 in AML Treatment

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.
ITWire

iTWireTV Interview: Cabital's new Aussie AML Compliance Manager Luke Raven to help acquire regulatory approval in Australia

GUEST INTERVIEW: With anti money laundering (AML) and counter terrorism financing (CTF) management a vital part of any financial organisation, and especially so for crypto and digital assets companies ...
Yahoo Finance

2024 KOL Interview on Acute Myeloid Leukemia (AML) Treatment in Southern US: Expert Insights and Emerging Therapies - Magrolimab, Quizartinib, Crenolanib, Gilteritinib, and ...

Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) KOL Interview - US, South" report has been added to ResearchAndMarkets.com's offering. This report presents an exclusive ...
ITWire

VIDEO Interview: Cabital's new Aussie AML Compliance Manager Luke Raven to help acquire regulatory approval in Australia

GUEST INTERVIEW: With anti money laundering (AML) and counter terrorism financing (CTF) management a vital part of any financial organisation, and especially so for crypto and digital assets companies ...